Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital

Korean Journal of Internal Medicine

Volumn 29, Issue 1, 2014, Pages 49-56

  Lee, Shinwon ^a   Han, Seung Woo ^a   Kim, Kun Woo ^a   Song, Do Young ^a   Kwon, Ki Tae ^a  

^a Daegu Fatima Hospital   (South Korea)

Author keywords

Bacteremia; Emergency department; Escherichia coli; Klebsiella pneumonia; Secondary hospital

Indexed keywords

AMIKACIN; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TOBRAMYCIN;

ABDOMINAL INFECTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMMUNICABLE DISEASE; DEMOGRAPHY; DRUG EXPOSURE; EMERGENCY WARD; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RISK FACTOR; SECONDARY CARE CENTER; URINARY TRACT INFECTION; COMMUNITY ACQUIRED INFECTION; EMERGENCY HEALTH SERVICE; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BACTEREMIA; CEPHALOSPORIN RESISTANCE; COMMUNITY-ACQUIRED INFECTIONS; EMERGENCY SERVICE, HOSPITAL; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SECONDARY CARE CENTERS;

EID: 84894613846     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2014.29.1.49     Document Type: Article

References (24)

1. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999;29:595-607.
2. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-e120.
3. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-164.
4. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001;33:48-53.
5. Ena J, Lopez-Perezagua MM, Martinez-Peinado C, Cia- Barrio MA, Ruiz-Lopez I. Emergence of ciprof loxacin resistance in Escherichia coli isolates after widespread use of f luoroquinolones. Diagn Microbiol Infect Dis 1998;30:103-107.
6. Lee H, Kim CK, Lee J, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2005 and 2006. Korean J Clin Microbiol 2007;10:59-69.
7. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Canton R, Baquero F. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community-and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010;54:3043-3046.
8. Pitout JD, Gregson DB, Church DL, Laupland KB. Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis 2007;13:443-448.
9. Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010;50:40-48.
10. Kang CI, Song JH, Chung DR, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2010;36:284-287.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
12. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004;140:26-32.
13. Courpon-Claudinon A, Lefort A, Panhard X, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect 2011;17:557-565.
14. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R; BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008;62 Suppl 2:ii41-ii54.
15. Wang P, Hu F, Xiong Z, et al. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol 2011;49:3127-3131.
16. Song W, Lee H, Lee K, et al. CTX-M-14 and CTX-M-15 enzymes are the dominant type of extended-spectrum beta-lactamase in clinical isolates of Escherichia coli from Korea. J Med Microbiol 2009;58(Pt 2):261-266.
17. Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004;25:860-867.
18. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481-1491.
19. Menashe G, Borer A, Yagupsky P, et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001;33:188-193.
20. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006;50:1257-1262.
21. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006;50:498-504.
22. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686.
23. Kang CI, Park SY, Chung DR, Peck KR, Song JH. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect 2012;64:533-534.
24. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A; Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patología Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group. β-Lactam/ β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-174.